These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23466360)

  • 21. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
    Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation.
    Acher PL; Popert R; Morris SL; Potters L; Austin-Smith SL; Johnson UH; Nichol JE; Beaney RP
    BJU Int; 2007 May; 99(5):1066-71. PubMed ID: 17233801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry.
    Sanders JW; Tang C; Kudchadker RJ; Venkatesan AM; Mok H; Hanania AN; Thames HD; Bruno TL; Starks C; Santiago E; Cunningham M; Frank SJ
    Brachytherapy; 2023; 22(6):822-832. PubMed ID: 37716820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: correlation with postimplant CT scan parameters.
    Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
    Strahlenther Onkol; 2006 Nov; 182(11):660-5. PubMed ID: 17072524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of urinary morbidity in Cs-131 prostate brachytherapy implants.
    Smith RP; Jones HA; Beriwal S; Gokhale A; Benoit R
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):745-50. PubMed ID: 20888139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years.
    Stone NN; Stock RG
    Urology; 2007 Feb; 69(2):338-42. PubMed ID: 17320674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
    Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
    J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost.
    Ben Aicha I; Hathout L; Carignan D; Després P; Lavallée MC; Aubin S; Beaulieu L; Lacroix F; Foster W; Martin AG; Vigneault E
    Brachytherapy; 2020; 19(5):584-588. PubMed ID: 32928485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
    Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
    Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
    Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
    Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
    Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J
    Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life.
    Harris AA; Wu M; Deirmenjian JM; Shea SM; Kang H; Patel R; Fielder D; Mysz ML; Harkenrider MM; Solanki AA
    Brachytherapy; 2021; 20(1):66-74. PubMed ID: 33160849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.
    Hanlon AL; Watkins Bruner D; Peter R; Hanks GE
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is intraoperative nomogram-based overplanning of prostate implants necessary?
    D'Souza WD; Lee HK; Palmer MB; Smith LG; Pollack A
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):462-7. PubMed ID: 12738321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
    Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term experience with 3D image guided brachytherapy and clinical outcome in cervical cancer patients.
    Ribeiro I; Janssen H; De Brabandere M; Nulens A; De Bal D; Vergote I; Van Limbergen E
    Radiother Oncol; 2016 Sep; 120(3):447-454. PubMed ID: 27157510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.